On Feb. 23, 2015, a bankruptcy judge approved the sale of the assets of Dendreon Corp., a Seattle-based cancer drug company founded in 1992, to Valeant Pharmaceuticals for $495 million.

Dendreon filed for Chapter 11 protection in September 2014 after it primary drug candidate, Provenge proved unattractive to doctors and patients. A standard course of treatment cost $93,000, and the results showed a four-month improvement in median survival rate.

In 2017, China’s Sanpower Group acquired Dendreon from Valeant Pharmaceuticals for $820 million, and one later, sold the company to Nanjing Cenbest for $868 million.